Vir Biotechnology, Inc. VIR
10.66
(0.06)
(0.56%)
as of 25 Sep
- Market cap
- $1.8B
- P/E
- 0.0×
Follow VIR
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(49.06%) | (45.73%) | (47.69%) | (26.08%) | |
| (39.69%) | (36.47%) | (37.95%) | (20.91%) | ||
ROIC |
(119.31%) | (101.09%) | (88.19%) | (39.10%) | |
Return on Tangible Assets |
(94.51%) | (91.84%) | (88.09%) | (47.56%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.29) | (2.86) | (3.05) | (1.21) | |
Free Cash Flow |
(457.20) | (396.36) | (449.67) | (203.67) | |
Capital Expenditures |
(3.66) | (4.58) | (3.62) | (1.16) | |
Piotroski F-Score |
1.00 | 3.00 | 3.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(34.76%) | (31.74%) | (34.55%) | (13.35%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.10 | 0.10 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | — | — | |
Average Days of Payables |
3,404.84 | 5,039.57 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,809.61% | 665.10% | 681.34% | 159.62% | |
Selling, General and Administrative Expense of Revenue |
564.41% | 134.30% | 139.66% | 32.77% | |
Share Based Compensation of Revenue |
318.55% | 71.58% | 71.91% | 15.51% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.91 | 0.89 | 1.01 | 0.80 | |
Depreciation/Fixed assets |
0.37 | 0.38 | 0.33 | 0.30 | |
Capex/Depreciation |
(0.17) | (0.22) | (0.21) | (0.08) | |
Revenue per Share |
0.12 | 0.49 | 0.44 | 1.81 | |
Operating CF per Share |
(3.26) | (2.83) | (3.03) | (1.21) | |
Capex per Share |
(0.03) | (0.03) | (0.02) | (0.01) | |
Capex to Sales |
0.22 | 0.07 | 0.06 | 0.00 | |
Net Profit Margin |
(2,963.54%) | (638.87%) | (675.96%) | (83.00%) |
Columns are period end dates